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ABSTRACT
Background: Tuberculosis is the most common opportunistic infection among HIV-infected patients 
in Brazil. Brazil’s national policy for HIV care recommends screening for latent tuberculosis (TB) and 
implementing isoniazid preventive therapy (IPT). Objectives: We compared physician adherence to 
TB screening and other prevention and care policies among HIV primary care clinics in Rio de Janeiro 
City. Methods: Data on performance of CD4 counts, viral load testing, tuberculin skin testing (TST) 
and IPT were abstracted from patient charts at 29 HIV clinics in Rio de Janeiro as part of the TB/HIV 
in Rio (THRio) study. Data on use of pneumocystis jiroveci pneumonia (PCP) prophylaxis were also 
abstracted from a convenience sample of 150 patient charts at 10 HIV clinics. Comparisons were made 
between rates of adherence to TB guidelines and other HIV care guidelines. Results: Among the sub-
set of 150 patients with confirmed HIV infection in 2003, 96% had at least one reported CD4 counts 
result; 93% had at least one viral load result reported; and, PCP prophylaxis was prescribed for 97% of 
patients with CD4 counts < 200 cells/mm3 or when clinically indicated. In contrast, 67 patients (45%) 
had a TST performed (all eligible); and only 11% (17) of eligible patients started IPT. Among 12,027 
THRio cohort participants between 2003 and 2005, the mean number of CD4 counts and viral load 
counts was 2.5 and 1.9, respectively, per patient per year. In contrast, 49% of 8,703 eligible patients in 
THRio had a TST ever performed and only 53% of eligible patients started IPT. Conclusion: Physicians 
are substantially more compliant with HIV monitoring and PCP prophylaxis than with TB prophylaxis 
guidelines. Efforts to improve TB control in HIV patients are badly needed. 
Keywords: AIDS-related opportunistic infections; tuberculosis; disease prevention; guideline 
adherence.
[Braz J Infect Dis 2011;15(3):249-252]©Elsevier Editora Ltda.
INTRODUCTION
Tuberculosis (TB) is the most common oppor-
tunistic infection among HIV-infected patients 
in Brazil.1 Among reported AIDS cases in Rio de 
Janeiro city, TB is diagnosed within one year in 
15-18%,2 and TB is the cause of death in approxi-
mately 10% of all AIDS deaths.3 The universal 
availability of HAART in Brazil has led to a re-
duction in the incidence of opportunistic diseases 
such as Pneumocystis jiroveci pneumonia (PCP),4 
but has had much less of an impact on TB.2 
Brazil’s national policy for HIV care rec-
ommends at least three CD4-cell counts and 
viral load measurements per year, regardless of 
antiretroviral use. Annual screening for latent 
TB infection with a tuberculin skin test (TST) 
and provision of isoniazid preventive therapy 
(IPT) for patients with a TST result > 5 mm of 
induration is also recommended. In addition, 
HIV-infected patients with WHO stages 3 or 4 
disease or a CD4-cell count < 200/mm3 should 
receive co-trimoxazole prophylaxis for PCP.5 
Physician adherence to guidelines varies by 
disease and is often dependent on a variety of 
factors.6,7 For AIDS and HIV infection, guide-
lines first appeared early in the epidemic,8 fo-
cusing primarily on diagnostic and preventive 
measures. In recent years, focus has moved to-
wards monitoring and treatment of HIV infec-
tion with antiretroviral (ARV) agents. A pre-
vious report showed that Brazilian physicians 
have good adherence to national guidelines, 
but the study mainly focused on ARV manage-
ment.9 Little information has been available re-
garding adherence to TB-related guidelines in 
HIV-infected patients in Brazil.
We compared physician adherence to 
guidelines for HIV-infected patients in Brazil, 
with special attention to latent TB screening 
and provision of isoniazid preventive therapy 
versus other HIV care policies. 
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METHODS
The study was conducted within the TB/HIV in Rio de Ja-
neiro (THRio) study, a cluster randomized trial promot-
ing TST and use of IPT in HIV clinics in Rio de Janeiro, 
Brazil.10 Clinical and laboratory data, including CD4-cell 
count, viral load, TST, and IPT data, are regularly ab-
stracted from patient charts at 29 HIV clinics participat-
ing in THRio study. Trained abstractors used standard-
ized data collection forms to obtain information on all 
patients seen in the HIV clinics after September 1st 2003, 
and accuracy was assured by reabstraction and routine 
quality control measures. For the current analysis, we used 
data collected in the first round of chart abstractions in 
2005-2006, covering clinical care for all patients active 
from the start of the study until the date of abstraction. 
To obtain data on provision of PCP prophylaxis, which is 
not part of the THRio database, we abstracted additional 
information from the charts of 150 patients at 10 of the 
study clinics using a structured data collection tool. 
The patients represent a convenience sample of 15 medi-
cal charts at each health center among patients seen on 
the day prior to data collection.
We considered all patients receiving HIV care in the 
clinics to be eligible to receive CD4 and viral load monitor-
ing, which was recommended thrice annually regardless of 
stage of disease or use of antiretroviral therapy. According 
to guidelines, patients eligible for TST were those without 
a prior history of active TB or a positive TST in the past, and 
each eligible patient was to be tested at least once annually. IPT 
was considered indicated in those with TST results > 5 mm 
induration and without active TB disease. Co-trimoxazole 
prophylaxis was considered indicated in patients with a CD4 
count < 200/mm3 or with WHO stage 3 or 4 disease.5
Descriptive statistical analysis compared adherence with 
specific guidelines either in the entire sample or within the 
subset of 150 patients for whom PCP prophylaxis data were 
available. 
RESULTS 
Among the 12,027 HIV-infected patients in the THRio 
database with follow up between September 1st 2003 and 
September 1st 2005, 95% (11,403/12,027) had at least one 
reported CD4 count and 94% had at least one reported vi-
ral load result. The rate of CD4 cell counts per person was 
2.5/year and the rate of viral load quantifications per per-
son was 1.9/year. In contrast, 4,804 of 8,703 (49%) patients 
eligible to have a TST placed had one prior to the initiation 
of the study. Of those with positive tests and no active TB, 
778 (53%) were given IPT (Table 1).
Among the 150 patients in our convenience sample, 
all had indications for PCP prophlyaxis at some point in 
time and 145 (97%) had received co-trimoxazole. Ninety-
six percent of patients (144) had at least one reported CD4 
and 93% (139) had at least one reported viral load; mean 
time between a request for CD4 and viral load tests and 
its registration in the chart was 3.7 months. For 111 patients 
(74%), lipid levels were recorded and reference to adherence 
to therapy was found in 108 charts (81%). In contrast, 67 pa-
tients (45%) had a tuberculin skin test performed and only 
11% patients started IPT ever (Table 2). 
Table 1. Mean number of CD4 and viral load tests per year and proportion of patients with a TST applied per 
year, THRio cohort
Test No. patients tested/number eligible Mean number per patient or proportion 
CD4-count  11,403/12,027 2.52 p/year*
Viral load  11,264/12,027 1.94 p/year*
TST  4,804/8,703 16.2%/year
* National guidelines recommend at least 3 per year
Table 2. Proportion of HIV-infected patients receiv-
ing care recommended by national guidelines,  
Rio de Janeiro, Brazil (n = 150)
Guidelines Proportion Number/n eligible
PCP prophylaxis 97 145/150
CD4 results 96 144/150
Viral load results 93 139/150
TST applied 45 67/150
IPT 11 17/150
DISCUSSION
Our study has shown that physician adherence to HIV 
guidelines in Rio de Janeiro City is quite high for PCP 
prophylaxis and moderate to low with routine monitor-
ing of standard HIV clinical markers. However, adherence 
is quite poor for detection and treatment of latent tubercu-
losis infection among HIV-infected patients. Rio de Janei-
ro City has a high burden of tuberculosis11 and a relatively 
low HIV prevalence in the general population.4 TB is the 
most common opportunistic infection among HIV-positive 
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patients and TB accounts for almost 10% of the underlying 
cause of death among those reported as AIDS cases.3 Despite 
this burden, detection and treatment of latent tuberculosis 
infection is relatively ignored by HIV/AIDS physicians.
In the pre–antiretroviral era, PCP was the most im-
portant cause of sickness and death in the HIV epidemic, 
and prescribing co-trimoxazole was quickly seen as a life 
saving action.12 In our study, 97% of the patients had been 
prescribed a PCP prophylaxis drug, most commonly 
co-trimoxazole, when their CD4 counts were below 
200 cells/mm3 or when the patient had symptoms related to 
HIV progression and no CD4 results available. Thus, physi-
cians have continued to prescribe this preventive medication 
according to guidelines. Using targeted physician feedback, 
Montaner et al.13 showed an increase in adherence to guide-
lines for PCP prevention from 29% to 61% and an increase 
in TST provision from 43% to 65% in Vancouver, Canada 
between 1990 and 1993. However, baseline data collected 
for the THRio study14 revealed a low proportion of patients 
receiving TST and IPT, despite guidelines recommending 
these measures since 1994.1
Many barriers have been described while looking for phy-
sician non-adherence to well-established evidence–based 
clinical protocols.7 Our findings are in concordance with 
studies conducted in other settings, both in the developed15-17 
and developing countries.18 Physicians did not request a TST 
for 36% of eligible HIV positive patients in New York City 
in 199515 and Lee et al.16 found a slightly higher proportion 
(46%) of patients without a TST in three other US cities. In 
both studies, an association between having a TST placed 
and a greater number of visits to clinics was reported and 
in New York City, an association with a written clinic policy 
for TST screening in HIV positive patients was detected.16 
A survey among physicians with 630 respondents in San 
Francisco Area Bay, US (350 of which were involved in HIV 
care), suggested that physician’s experience in HIV care pre-
dicted adherence to IPT guidelines,18 while a similar find-
ing was reported in Italy though 29% still did not receive a 
TST.17 In Thailand, only 19% of physicians provided IPT to 
their patients despite a national recommendation for provi-
sion of IPT for people living with HIV.19 Moreover, they were 
not attentive to excluding active TB, as only 35% of the doc-
tors requested a chest x-ray prior to IPT initiation.
Placement of a tuberculin skin test followed by IPT when 
indicated requires a commitment both from physicians and 
patients, as more clinic visits are required and adherence to 
another medication must be considered. Ruling out active 
TB is a requirement before starting IPT and includes symp-
tom screening, sputum smear microscopy and a chest radio-
graph. These extra steps may discourage a physician from 
testing for latent TB infection. Furthermore, in a qualitative 
study done with physicians in Rio de Janeiro,20 concerns 
about isoniazid toxicity were the reason stated for not ad-
hering to guidelines. Although there is evidence of the low 
toxicity of isoniazid among HIV patients,21 and the e! cacy 
of IPT in reducing tuberculosis has been shown,14 fear of 
toxicity22 and ruling out active disease likely contribute to 
the poor uptake. 
There are some limitations for our study. First, the con-
venience sample was a small one when compared to the 
study, but it allowed us to get important information both 
on PCP and TB prophylaxis, which resulted in more discus-
sion about both topics in the TB/HIV training activities that 
were implemented in the 29 clinics during to the study. Sec-
ond, no data on PCP prophylaxis was collected thereafter for 
follow-up on the comparison. On the other hand, this study 
was critical to establish the baseline level of TST and IPT 
coverage in those clinics. 
Thus, the e! cacy of IPT at reducing the burden of TB 
among HIV–positive patients must be disseminated among 
doctors and the HIV community. Furthermore, the process 
of ruling out TB should be seen as an opportunity to detect 
active cases of TB for early treatment and reduction of mor-
tality and transmission of TB. New evidence from the WHO 
should alleviate some of the fears associated with ruling out 
active TB disease.23
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